| Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open … J Finke, WA Bethge, C Schmoor, HD Ottinger, M Stelljes, AR Zander, ... The lancet oncology 10 (9), 855-864, 2009 | 799 | 2009 |
| International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium AC Harris, R Young, S Devine, WJ Hogan, F Ayuk, U Bunworasate, ... Biology of Blood and Marrow Transplantation 22 (1), 4-10, 2016 | 653 | 2016 |
| Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell … T Feuchtinger, K Opherk, WA Bethge, MS Topp, FR Schuster, ... Blood, The Journal of the American Society of Hematology 116 (20), 4360-4367, 2010 | 540 | 2010 |
| Antilymphocyte globulin for prevention of chronic graft-versus-host disease N Kröger, C Solano, C Wolschke, G Bandini, F Patriarca, M Pini, A Nagler, ... New England Journal of Medicine 374 (1), 43-53, 2016 | 534 | 2016 |
| Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party … N Kröger, E Holler, G Kobbe, M Bornhäuser, R Schwerdtfeger, ... Blood, The Journal of the American Society of Hematology 114 (26), 5264-5270, 2009 | 470 | 2009 |
| Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation … A Burchert, G Bug, LV Fritz, J Finke, M Stelljes, C Röllig, E Wollmer, ... Journal of Clinical Oncology 38 (26), 2993-3002, 2020 | 413 | 2020 |
| Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies ML Sorror, BM Sandmaier, BE Storer, GN Franke, GG Laport, ... Jama 306 (17), 1874-1883, 2011 | 336 | 2011 |
| Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius G Socié, C Schmoor, WA Bethge, HD Ottinger, M Stelljes, AR Zander, ... Blood, The Journal of the American Society of Hematology 117 (23), 6375-6382, 2011 | 332 | 2011 |
| Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell … V Icheva, S Kayser, D Wolff, S Tuve, C Kyzirakos, W Bethge, J Greil, ... J Clin Oncol 31 (1), 39-48, 2013 | 304 | 2013 |
| Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation R Storb, B Gyurkocza, BE Storer, ML Sorror, K Blume, D Niederwieser, ... Journal of Clinical Oncology 31 (12), 1530, 2013 | 264 | 2013 |
| Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ... Nature medicine 24 (3), 282-291, 2018 | 263 | 2018 |
| Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia H Pfeifer, B Wassmann, W Bethge, J Dengler, M Bornhäuser, M Stadler, ... Leukemia 27 (6), 1254-1262, 2013 | 255 | 2013 |
| Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia B Gyurkocza, R Storb, BE Storer, TR Chauncey, T Lange, JA Shizuru, ... Journal of clinical oncology 28 (17), 2859, 2010 | 251 | 2010 |
| CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma K Rejeski, A Perez, P Sesques, E Hoster, C Berger, L Jentzsch, ... Blood, The Journal of the American Society of Hematology 138 (24), 2499-2513, 2021 | 243 | 2021 |
| Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study … N Kröger, S Iacobelli, GN Franke, U Platzbecker, R Uddin, K Hübel, ... Journal of Clinical Oncology 35 (19), 2157-2164, 2017 | 241 | 2017 |
| Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change M Christopeit, O Kuss, J Finke, U Bacher, DW Beelen, M Bornhäuser, ... Journal of clinical oncology 31 (26), 3259-3271, 2013 | 186 | 2013 |
| Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning C Kahl, BE Storer, BM Sandmaier, M Mielcarek, MB Maris, KG Blume, ... Blood, The Journal of the American Society of Hematology 110 (7), 2744-2748, 2007 | 185 | 2007 |
| Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update WA Bethge, C Faul, M Bornhäuser, G Stuhler, DW Beelen, P Lang, ... Blood Cells, Molecules, and Diseases 40 (1), 13-19, 2008 | 176 | 2008 |
| Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders GG Laport, BM Sandmaier, BE Storer, BL Scott, MJ Stuart, T Lange, ... Biology of Blood and Marrow Transplantation 14 (2), 246-255, 2008 | 165 | 2008 |
| GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany WA Bethge, P Martus, M Schmitt, U Holtick, M Subklewe, B von Tresckow, ... Blood, The Journal of the American Society of Hematology 140 (4), 349-358, 2022 | 162 | 2022 |
